Unity biotechnology, inc. (UBX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-28,038

-18,027

-21,710

-23,673

-18,767

-21,916

-18,347

-20,002

-16,133

-12,543

-11,751

-11,428

-8,934

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

903

745

638

643

637

596

561

521

502

468

448

294

94

Net accretion and amortization of premium and discounts on marketable securities

63

116

269

400

366

369

383

170

33

-

-

-

-

Amortization of premium and discounts on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

13

Stock-based compensation

3,317

3,088

3,823

1,944

1,997

2,516

2,717

2,838

1,370

1,537

559

525

413

Non-cash rent expense

461

-

-

-

400

-

-

-

-

-

-

-

-

Impairment of long-lived assets

2,159

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of strategic investment

-1,387

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of tenant improvement allowance

-

402

403

318

152

149

151

153

152

152

151

151

151

Change in fair value of contingent consideration

-221

-

-

-

-1,245

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Contribution receivable

-

-

-

-

-

0

0

0

-1,382

-

-

-

-

Prepaid expenses and other current assets

-123

-250

-347

954

-188

-173

353

953

-291

-52

285

194

319

Other long-term assets

-29

6

8

8

9

-502

7

1,095

4

1

1

1

-26

Accounts payable

-1,345

104

-722

1,167

-776

2,137

724

-2,463

1,830

-2,254

1,654

753

1,045

Accrued compensation

-3,675

2,233

931

1,067

-2,117

952

898

983

-1,223

-

-

-

-

Accrued compensation

-

-

-

-

-

-

-

-

-

-

-

-

-190

Accrued and other current liabilities

-110

-85

529

-1,096

65

606

-130

731

239

1,771

-287

-160

-66

Deferred rent, net of current portion

-

1,057

1,125

330

-51

-48

-49

-44

48

-

-

-

-

Deferred rent, net of current portion

-

-

-

-

-

-

-

-

-

-

-

54

209

Net cash used in operating activities

-25,073

-15,691

-16,833

-19,301

-20,596

-12,806

-13,885

-18,049

-11,883

-11,600

-9,121

-9,777

-7,860

Investing activities
Purchase of marketable securities

36,950

29,112

39,459

32,645

18,054

38,016

28,267

131,578

6,225

14,170

10,010

51,071

59,214

Maturities of marketable securities

40,650

25,249

65,080

40,159

58,321

37,975

37,185

39,211

19,273

-

-

-

-

Purchase of property and equipment

34

609

540

230

207

448

290

425

101

326

379

690

294

Net cash provided by investing activities

3,666

-4,472

25,081

7,284

40,060

-989

8,628

-92,792

12,947

8,943

11,271

-47,011

-59,508

Financing activities
Proceeds from issuance of common stock under ATM Offering Program, net of issuance costs

8,763

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-18

0

4,948

54,951

-1

-12

34,896

7,984

Proceeds from issuance of common stock upon exercise of stock options, net of repurchases

249

-

-

-

300

-

-

-

27

-

-

-

-

Other financing cash flows

-19

-

-

-

-18

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options, net of repurchases

-

-

-

-

-

-

-

-

-

-

-

-

2

Payment of initial public offering costs

-

-

-

-

-

0

2

2,630

569

-

-

-

-

Payments made on capital lease obligations

-

-

-

-

-

22

18

17

17

-

-

-

-

Net cash provided by financing activities

8,993

20,868

5,407

881

282

297

-11

82,252

54,392

-12

-87

34,888

7,986

Net increase (decrease) in cash, cash equivalents and restricted cash

-12,414

705

13,655

-11,136

19,746

-

-

-

-

-

-

-

-

Net increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

55,456

-

2,063

-21,900

-59,382

Supplemental Disclosures of Non-Cash Investing and Financing Activities
Property and equipment included in accounts payable and accrued liabilities

302

503

15

-24

71

86

17

104

34

11

-225

402

126

Issuance of shares in settlement of share-based liability

100

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock to settle contingent consideration liability

-

-

-

-

2,059

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

1,138

-

-

-

-

Receipt of promissory note from related party for purchase of common stock

-

-

-

-

-

0

0

0

390

-

-

-

-

Receipt of promissory note from employees for purchase of common stock

-

-

-

-

-

-

0

0

400

-

-

-

-